SeQuent Scientific Q3FY11 net profit up 14.3% at Rs 4.03 cr

Q3FY11 Total income at Rs 67.98 cr, up 5.0%

SeQuent Scientific Limited (SeQuent), a leading Indian active pharmaceutical ingredient company having presence in Human and Veterinary segments, today announced the unaudited results for the quarter ending 31st December, 2010 (Q3FY11).

Q3FY11 Performance

• The Company’s total revenues increased by 5.0% to Rs. 67.98 crore as compared to Rs. 64.73 crore during Q3FY10
• Net profit was up by 14.3% to Rs. 4.03 crore as compared to Rs. 3.53 crore during Q3FY10
• EBITDA increased by 14.1% to Rs. 13.57 crore as compared to Rs. 11.88 crore 
• The EBIDTA margin improved by 160 basis points to 19.9% (as compared to 18.3% during Q3FY10).
• The net margin also registered an improvement of 40 basis points to 5.9% (as compared to 5.5% during Q3FY10)
• On an Equity share capital of Rs. 21.93 crore, the company’s Earnings per share (EPS) stood at Rs. 1.84 (10.8% up).

Q3FY11 Segmental Performance

• The company’s Pharmaceuticals segment (comprising of Human API, Veterinary API and Veterinary Formulations businesses) accounted for 78.9% of the total revenues during Q3FY11 as compared to 82.9% during Q3FY10
• Pharmaceuticals segment also accounted for 72.7% of the Company’s EBIDTA as compared to 70.6% during Q3FY10
• Specialty chemicals segment accounted for 21.1% of the total revenues (17.1% in Q3FY10) and 27.3% of total EBIDTA (29.4% in Q3FY10)
• In terms of EBIDTA margins, Pharmaceutical segment stood at 15.1% and Specialty chemicals registered 21.2% margin during Q3FY11

9M FY11 Performance
(9MFY11 – April-December 2010); (9MFY10 – April-December 2009)

• Posted a 4.8% increase in total operational income to Rs. 201.53 crore as compared to Rs. 192.26 crore in 9MFY10
• Net profit for period under review was Rs. 15.22 crore as compared to Rs. 18.89 crore in 9MFY10
• EBITDA stood at Rs. 35.09 crore as compared to Rs. 50.75 crore in 9MFY10

About SeQuent Scientific Limited
SeQuent Scientific Limited is a fast growing active pharmaceutical ingredient company with global footprints, having presence in Human and Veterinary segments. The company has developed an integrated business model, based on its ability offer niche products and solutions in Human & Veterinary API, Veterinary formulations, Specialty chemicals and CRAMS segments. Headquartered in Mumbai, SeQuent has seven state-of-the-art manufacturing facilities across India, including a world-class research facility in Mangalore, Karnataka. SeQuent’s facilities are ISO and cGMP certified.